Ratings by Truist Securities (Gregory Fraser)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/1/2024 | ANI Pharmaceuticals | ANIP | Maintain | Buy (N/A) |
|
Details | ||
| 2/16/2024 | ANI Pharmaceuticals | ANIP | Maintain | Buy (N/A) |
|
Details | ||
| 1/18/2024 | biote Corp. | BTMD | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2023 | Beyond Air | XAIR | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | ANI Pharmaceuticals | ANIP | Maintain | Buy (N/A) |
|
Details | ||
| 5/26/2023 | Corcept Therapeutics | CORT | Maintain | Hold (N/A) |
|
Details | ||
| 5/9/2023 | ANI Pharmaceuticals | ANIP | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | NovoCure Ltd. | NVCR | Maintain | Buy (N/A) |
|
Details | ||
| 2/17/2023 | Organon & Co. | OGN | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2023 | Beyond Air | XAIR | Maintain | Buy (N/A) |
|
Details | ||
| 1/6/2023 | RVL Pharmaceuticals plc | RVLP | Maintain | Buy (N/A) |
|
Details | ||
| 1/6/2023 | ANI Pharmaceuticals | ANIP | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2022 | Corcept Therapeutics | CORT | Maintain | Hold (N/A) |
|
Details | ||
| 11/3/2022 | Organon & Co. | OGN | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2022 | NovoCure Ltd. | NVCR | Maintain | Buy (N/A) |
|
Details | ||
| 9/27/2022 | biote Corp. | BTMD | New Coverage | Buy (N/A) |
4.21 (5.59) |
32.78% | Details | |
| 8/23/2022 | Aerie Pharma | AERI | Downgrade | Hold (Buy) |
11.15 (15.25) |
36.77% | Details | |
| 8/22/2022 | Aerie Pharma | AERI | Maintain | Buy (N/A) |
|
Details | ||
| 8/1/2022 | Organon & Co. | OGN | Maintain | Buy (N/A) |
|
Details | ||
| 8/1/2022 | Aerie Pharma | AERI | Maintain | Buy (N/A) |
|
Details | ||
| 8/1/2022 | Corcept Therapeutics | CORT | Downgrade | Hold (Buy) |
28.66 (22.48) |
-21.56% | Details | |
| 7/29/2022 | NovoCure Ltd. | NVCR | Maintain | Buy (N/A) |
|
Details | ||
| 7/29/2022 | Bausch Health Companies | BHC | Downgrade | Hold (Buy) |
8.68 (8.56) |
-1.38% | Details | |
| 6/29/2022 | Beyond Air | XAIR | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2022 | Clarus | CRXT | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2022 | NovoCure Ltd. | NVCR | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2022 | ANI Pharmaceuticals | ANIP | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2022 | BioDelivery Sciences International | BDSI | Downgrade | Hold (Buy) |
5.57 (5.59) |
0.36% | Details | |
| 2/25/2022 | NovoCure Ltd. | NVCR | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2022 | Corcept Therapeutics | CORT | New Coverage | Buy (N/A) |
16.53 (22.48) |
36% | Details | |
| 1/20/2022 | RVL Pharmaceuticals plc | RVLP | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2022 | Organon & Co. | OGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2022 | Clarus | CRXT | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2022 | BioDelivery Sciences International | BDSI | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2022 | Aerie Pharma | AERI | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2022 | NovoCure Ltd. | NVCR | Upgrade | Buy (Hold) |
64.18 (12.34) |
-80.77% | Details | |
| 11/12/2021 | Beyond Air | XAIR | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2021 | ANI Pharmaceuticals | ANIP | New Coverage | Buy (N/A) |
55.89 (65.43) |
17.07% | Details | |
| 10/13/2021 | Clarus | CRXT | New Coverage | Buy (N/A) |
4.10 (0.10) |
-97.56% | Details | |
| 4/28/2021 | Beyond Air | XAIR | New Coverage | Buy (N/A) |
5.47 (1.28) |
-76.6% | Details |
